Longitudinal study of childhood nephrotic syndrome
Official title: INSIGHT (Insight Into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics)
Run by The Hospital for Sick Children · NCT01605266 · Data updated 2026-11-12
This study looks at children with nephrotic syndrome to see how genetics, blood tests, and environmental factors affect the condition and its progression over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 6 Months to 18 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | The Hospital for Sick Children Academic / other |
| Locations | 4 sites (Brampton, Ontario and 3 other locations) |
| Status | Recruiting |
| Started | January 2011 |
| Main results expected | January 2032 |
| Study ends | January 2032 |
| Registry record updated | October 25, 2022 |
| Trial ID | NCT01605266 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are children aged 6 months to 18 years diagnosed with nephrotic syndrome.
✕Probably not a fit
Patients with congenital nephrotic syndrome or syndromic diseases involving multiple organ systems may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
INSIGHT is a longitudinal observational study focused on childhood nephrotic syndrome, aiming to identify genetic, serologic, and environmental factors that contribute to the condition and its progression. The study involves a large multiethnic cohort and recruits participants from Toronto and surrounding regions, with plans to expand to additional sites in the future. By collecting data over time, the study seeks to test hypotheses regarding risk factors and disease outcomes in affected children.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of nephrotic syndrome in children.
How similar studies have gone: Other studies have explored genetic and environmental factors in nephrotic syndrome, but this specific longitudinal approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. diagnosis of nephrotic syndrome 2. signed informed consent and assent appropriate for age 3. ages 6 months -18 years old and 4. ability to complete questionnaires Exclusion Criteria: 1. congenital nephrotic syndrome (less than age 1) 2. syndromic disease with multiple organ involvement 3. inability to provide consent by primary care providers 4. conditions such as systemic lupus erythematous.
Where it's running
-
William Osler Health System, Brampton Civic Hospital and Peel Memorial Centre for Integrated Health and Wellness
Brampton, Ontario, Canada Recruiting -
Hamilton Health Sciences Corporation - McMaster University Medical Centre
Hamilton, Ontario, Canada Recruiting -
Rouge Valley Health System, Rouge Valley Centenary
Scarborough Village, Ontario, Canada Recruiting -
The Hospital for Sick Children
Toronto, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Rulan Parekh, MD — The Hospital for Sick Children
- Study coordinator: Rulan Parekh, MD
- Email: rulan.parekh@sickkids.ca
- Phone: 416-813-7654
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Smartphone app to help follow the 2024 KDIGO chronic kidney disease guidelines
This project will test whether a smartphone app helps young adults (ages 16–29) with chronic kidney disease follow the 2024 KDIGO guideline recommendations.
-
SGLT2 inhibitors added to standard care in adult primary nephrotic syndrome
This trial tests whether adding dapagliflozin or empagliflozin to standard treatment helps reduce protein in urine for adults with primary nephrotic syndrome.
-
Atacicept for multiple autoimmune glomerular diseases
This will test whether weekly injections of atacicept can lower protein in the urine and help preserve kidney function in people aged 10 and older with IgA nephropathy, primary membranous nephropathy, or nephrotic syndromes such as MCD and FSGS.
-
Multitarget approach for primary podocytopathies
This project will test whether a lab cell culture can find a factor in the blood that causes proteinuria in people with primary podocytopathies and whether a combined therapy can block that factor in vitro.
-
Follow-up on Rituximab treatment for children's nephrotic syndrome
This study looks at how well rituximab works and its safety for children with hard-to-treat nephrotic syndrome by reviewing their past treatment data.
-
Investigating the role of a protein in kidney damage related to nephrotic syndrome
This study is trying to see if a protein called PCSK9 is linked to kidney damage and high cholesterol in people with nephrotic syndrome.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.